参考文献/References:
［1］ FAHAD UILAH M.Breast cancer:current perspectives on the disease status［J］.Adv Exp Med Biol,2019,1152:51-64.
［2］ SHIGEMATSU H,FUJISAWA T,SHIEN T,et al.Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy［J］.Jpn J Clin Oncol,2020,50(6):629-634.
［3］ O′REILLY D,SENDI M A,KELLY C M.Overview of recent advances in metastatic triple negative breast cance［J］.World J Clin Oncol,2021,12(3):164-182.
［4］ YARSO K Y,BELLYNDA M,AZMIARDI A,et al.Chemotherapy negates the effect of SDF1 mRNA to distant metastasis and poor overall survival in breast cancer patients［J］.Asian Pac J Cancer Prev,2021,22(3):757-766.
［5］ PAGANI O,SESSA C,NOLE F,et al.Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer:a multicentric phase I-II study［J］.Ann Oncol,2017,11(8):985-991.
［6］ FIELDS E,WREN J D,GEORGESCU C,et al.Predictive bioinformatics identifies novel regulators of proliferation in a cancer stem cell model［J］.Stem Cell Res,2017,26(C):1-7.
［7］ JI W,SUN B,SU C.Targeting microRNAs in cancer gene therapy［J］.Genes,2017,8(1):21-36.
［8］ EI KILANY F H,YOUNESS R A,ASSAL R A,et al.miR-744/eNOS/NO axis:a novel target to halt triple negativebreast cancer progression［J］.Breast Dis,2021,published onlin ahead of print.DOI:3233/BD-200454.
［9］ YANG F,LI Y,XU L,et al.miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer［J］.Onco Targets Ther,2017,10:543-550.
［10］ LIN B,LIU C,SHI E,et al.MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4［J］.BMC Cancer,2021,21(1):275.
［11］ MANSSOORI B,SILVESTRIS N,MOHAMMADI A,et al.miR-34a and miR-200c have an additive tumor-suppressive effect on breast cancer cells and patient prognosis［J］.Genes (Basel),2021,12(2):267.
［12］ ZHAO J,FU Y,WU J,et al.The Diverse mechanisms of miRNAs and lncRNAs in the maintenance of liver cancer stem cells［J］.Biomed Research International,2018,2018:8686027.
［13］ WANG C,ZHOU B,LIU M,et al.miR-126-5p restoration promotes cell apoptosis in cervical cancer by targeting Bcl2l2［J］.Oncology Research,2017,25(4):463-470.
［14］ HE B,CHEN J,SONG W,et al.miR-646/TET1 mediated demethylation of IRX1 promoter upregulates HIST2H2BE and promotes the progression of invasive ductal carcinoma［J］.Genomics,2021,113(3):1469-1481.
［15］ LIN J,CHEN X,SUN M,et al.Upregulation of microRNA-181a-5p increases the sensitivity of HS578T breast cancer cells to cisplatin by inducing vitamin D receptor-mediated cell autophagy［J］.Oncol Lett,2021,21(4):247.
［16］ LIU J,ZHU S,TANG W,et al.Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p［J］.Cancer Cell Int,2021,21(1):55.
［17］ PAN X,HONG X,LI S,et al.METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner［J］.Exp Mol Med,2021,53(1):91-102.
［18］ CLIMANT J,DIMITRIW P,FRIDLYAND J,et al.Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer［J］.Cancer Research,2007,67(2):818-826.
［19］ XU X,LV Y G,YAN C Y,et al.Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling［J］.Biochem Biophys Res Commun,2016,479(4):893-900.
［20］ WANG Y,WANG H,DING Y,et al.N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer［J］.Int J Oncol,2017,51(3):918-930.
［21］ RAZA U,ZGE SAATCI,UHLMANNS,et al.The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer［J］.Oncotarget,2016,7(31):49859-49877.
［22］ LUO X,WANG H.LINC00514 upregulates CCDC71L to promote cell proliferation,migration and invasion in triple-negative breast cancer by sponging miR-6504-5p and miR-3139［J］.Cancer Cell Int,2021,21(1):180.
［23］ CHEN Z,SHI T,ZANG L,et al.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance:a review of the past decade［J］.Cancer Lett,2016,370(1):153-164.
［24］ CHEN J,TIAN W,CAI H,et al.Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer［J］.Med Oncol,2012,29(4):2527-2534.
［25］ ZHU Y,YU F,JIAO Y,et al.Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5［J］.Clin Cancer Res,2011,17(22):7105-7115.
［26］ UEDA S,TAKANASHI M,SUDO K,et al.miR-27a ameliorates chemoresistance of breast cancer cells by disruption of reactive oxygen species homeostasis and impairment of autophagy［J］.Lab Invest,2020,100(6):863-873.
［27］ LIANG L,FU J,WANG S,et al.MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1［J］.Acta Pharm Sin B,2020,10(6):1036-1046.
［28］ BAO C,CHEN J,CHEN D,et al.MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1［J］.Cell Death Dis,2020,11(8):618.
［29］ YU Z,CAO W,REN Y,et al.ATPase copper transporter A,negatively regulated by miR-148a-3p,contributes to cisplatin resistance in breast cancer cells［J］.Clin Transl Med,2020,10(1):57-73.
［30］ UAN X,GUAN Y.miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines［J］.Neoplasma,2020,67(5):972-981.
［31］ ZHANG P,YANG Y,QIAN K,et al.A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing HER2 expression in breast cancer［J］.J Biol Chem,2020,295(41):14140-14152.
［32］ GPOGRIBNY I P,FILKOWSKI J N,TRYNDYAK V P,et al.Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin［J］.Int J Cancer,2010,127(8):1785-1794.
［33］ HU H,LI S,CUI X,et al.The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2)［J］.J Biol Chem,2013,288(16):10973-10985.
［34］ YE X M,ZHU H Y,BAI W D,et al.Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R［J］.BMC Cancer,2014,14:134.
［35］ GAO Y,ZHANG W,LIU C,et al.miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB［J］.Sci Rep,2019,9(1):18844.
［36］ RAO X,DI LEVA G,LI M,et al.MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways［J］.Oncogene,2011,30(9):1082-1097.
［37］ FORONI C,BROGGINI M,GENERALI D,et al.Epithelial-mesenchymal transition and breast cancer:role,molecular mechanisms and clinical impact［J］.Cancer Treat Rev,2012,38(6):689-697.
［38］ HANSEN T B,JENSEN T I,CLAUSEN B H,et al.Natural RNA circles function as efficient microRNA sponges［J］.Nature,2013495(7441):384-388.
［39］ SMITH B,AGARWAL P,BHOWMICK N A.MicroRNA applications for prostate,ovarian and breast cancer in the era of precision medicine［J］.Endocrine-Related Cancer,2017,24(5):R157-R172.
［40］ MIRIHANA ARACHCHILAGE G,KHAREL P,REID J,et al.Targeting of G-Quadruplex harboring pre-miRNA 92b by LNA rescues PTEN expression in NSCL cancer cells［J］.Acs Chemical Biology,2018,13(4):909-914
［41］ HAN D,LI J,WANG H,et al.Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression［J］.Hepatology,2017,66(4):1151-1164.
［42］ YANG W,YANG X,WANG X,et al.Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ［J］.J Cell Mol Med,2019,23(8):4921-4932.
相似文献/References:
[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor，progestin recetor，Ki-67 antigen，and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(6):125.[doi:10.7683/xxyxyxb.2017.02.012]